Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22053372 | 0.81 | ADRB2 (0.48) | ADRB2SCN4ASLC6A4AOC3IDO1 | |
| SCHEMBL1953110 | 0.80 | ADRB2 (0.52) | ADRB2SCN4ASLC6A4TSHRSLC6A3 | |
| SCHEMBL393010 | 0.78 | ADRB2 (0.50) | ADRB2SCN4ASLC6A4AOC3IDO1 | |
| SCHEMBL14980665 | 0.78 | ANPEP (0.53) | ADRB2SCN4ASLC6A4IDO1TDO2 | |
| Hydrochloric Acid SCHEMBL28709083 | 0.78 | ADRB2 (0.50) | ADRB2SCN4ASLC6A4IDO1TDO2 | |
| Hydrochloric Acid SCHEMBL25367507 | 0.78 | ADRB2 (0.50) | ADRB2SCN4ASLC6A4IDO1TDO2 | |
| SCHEMBL1977034 | 0.78 | SLC6A4 (0.57) | ADRB2SCN4ASLC6A4AOC3IDO1 | |
| SCHEMBL16649759 | 0.78 | SLC6A4 (0.50) | ADRB2SCN4ASLC6A4IDO1TDO2 | |
| SCHEMBL390989 | 0.78 | SLC6A4 (0.57) | ADRB2SCN4ASLC6A4AOC3IDO1 | |
| SCHEMBL1307450 | 0.78 | ADRB2 (0.50) | ADRB2SCN4ASLC6A4AOC3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831532-B | It is complete to replace 3- nitroindoline compound and its midbody compound, preparation method and application | 云南大学 | 2019-03-08 | — | — | CN | disclosed |
| CN-106831532-A | Full substitution 3 nitroindoline compounds and its midbody compound, preparation method and application | 云南大学 | 2017-06-13 | — | — | CN | disclosed |
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| CN-102574818-B | Apaf-1 inhibitor compounds | SALVAT LAB SA | 2015-02-25 | — | — | CN | disclosed |
| CN-102712649-B | Benzimidazole derivatives and pharmaceutical compositions and uses thereof | SHANDONG XUANZHU MEDICINE SCIENCE AND TECHNOLOGY CO LTD | 2014-07-09 | — | — | CN | disclosed |
| CN-101970572-B | Photocurable composition | SEKISUI CHEMICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | Xuanzhu Pharma Co., Ltd. (CN) | 2013-01-24 | — | — | US | disclosed |
| EP-2532665-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| CN-1901916-A | Quinazolinone compounds with reduced in vivo accumulation | CHIRON CORP (US) | 2007-01-24 | — | — | CN | disclosed |
| CN-1829517-A | Guanidino-substituted quinazolines as MC 4-R agonists | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | F12, HRH2, H1-3 | ADRB2 747/4885SCN4A 1506/4885SLC6A4 3200/4885 |
| US-20130023568-A1 | Benzimidazole Derivatives And Their Pharmaceutical Compositions And Uses | F12, HRH2, H1-3 | ADRB2 747/4885SCN4A 1506/4885SLC6A4 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.